

GenScript and InnoBation enter into agreement for CAR-T therapy

18 December 2020 | News

GenScript will provide CRO services for developing engineered cell line complementing the latest immunotherapy technologies at InnoBation



A global leading biotech company GenScript Biotech Corporation announces that it has reached the agreement for cell line development and engineering, manufacture service of GMP Plasmids and Lentivirus with InnoBation Co., Ltd. a company that specializes in developing biomarkers and CAR-T cell treatment products.

InnoBation is a Republic of Korea based Biotech Company, currently working closely with the Korean National Cancer Center on the 'IBC 101' project, a bi-specific CAR-T therapy product, and several other CAR-T projects for hematological malignancies and solid tumors.

Through this agreement, GenScript will provide CRO services for developing engineered cell line using CRISPR CAS 9 technology and GenScript ProBio, the CDMO division of GenScript, will offer high-quality one-stop platform services of developing and manufacturing plasmid and lentivirus for preclinical and clinical trials, which would be required for InnoBation's CAR-T therapy development.

"We are delighted to reach collaboration with InnoBation in the field of CAR-T therapy. In recent years, the Republic of Korea has sprouted many innovative biotech companies, and InnoBation is one of leading innovative technology companies with the latest technology for immunotherapy." Yuyu Hu, Business development Head of GenScript Korea said, "We look forward to applying our superior process development capabilities together with InnoBation's insight into immunotherapeutic drug discovery and development to truly forge new frontiers in bringing personalized immunotherapies to patients."